ATVIVO

ATVIVO Laboratory
955 Yonkers Ave STE 19
Yonkers, NY 10704-3063
CLIA ID: 33D2149086

Toll free: (844) 788-1478
Fax: (844) 674-2886
Email: results@atvivo.com

Patient		Physician	
Last Name	CLXneg	**Last Name**	EllkayProvider
First Name	Test	**First Name**	Test
Middle Name		**Middle Name**	
Date of Birth	11/11/1999	**NPI#**	9999999991
MRN	A01787	**Address**	
Sex	Male		

Requisition ID	Collected	Received	Reported
220821AT00077	8/21/2022 9:51 AM	8/21/22 9:52 AM	8/21/2022 9:55 AM

Testing Ordered	SARS-Cov2 RT-PCR: Anterior Nasal	Collection Site	Nasopharyngeal

COVID19

TEST	RESULT	FLAG	REF. RANGE
SARS-Cov2 RT-PCR: Anterior Nasal	Negative		Negative

This test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in upper respiratory specimens (such as nasopharyngeal, oropharyngeal, nasal, and mid-turbinate swabs, and nasopharyngeal aspirate) and bronchoalveolar lavage (BAL) specimens from individuals suspected of COVID-19. The Applied Biosystems TaqPath COVID-19 Combo Kit is a fast, highly sensitive multiplex diagnostic solution that contains the assays and controls needed for the real-time PCR detection of RNA from the SARS-CoV-2 virus. The assay targets of spike (S) protein, ORF1ab region, and nucleocapsid (N) protein regions having higher specificity and exhibiting lower risk for mutation. The performance characteristics of the test were validated by ATVIVO laboratory in agreement with the FDA's Guidance Document "Policy for Diagnostics Testing in Laboratories Certified to Perform High Complexity Testing under CLIA prior to Emergency Use Authorization for Coronavirus Disease-2019 during the Public Health Emergency" issued on February 29th,2020. The TaqPath COVID-19 Combo Kit is for use only under Emergency Use Authorization (EUA). Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. Inconclusive results are reported when only one out of the three assay targets is amplified. In case of inconclusive results, the healthcare provider should conduct additional confirmation testing with a new specimen, if clinically indicated

********** END OF REPORT **********

Laboratory Director	Adila Nathu, MD